The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A)
Open accessAbstract
Fabry disease (alpha-galactosidase A (alpha-Gal A, GLA) deficiency) is a panethnic inborn error of glycosphingolipid metabolism. Because optimal therapeutic outcomes depend on early intervention, a pilot program was designed to assess newborn screening for this disease in 171,977 consecutive Taiwanese newborns by measuring their dry blood spot (DBS) alpha-Gal A activities and beta-galactosidase/alpha-Gal A ratios. Of the 90,288 male screenees, 638 (0.7%) had DBS alpha-Gal A activity <30% of normal mean and/or activity ratios >10. A second DBS assay reduced these to 91 (0.1%). Of these, 11 (including twins) had <5% (Group-A), 64 had 5-30% (Group-B), and 11 had >30% (Group-C) of mean normal leukocyte alpha-Gal A activity. All 11 Group-A, 61 Group-B, and 1 Group-C males had GLA gene mutations. Surprisingly, 86% had the later-onset cryptic splice mutation c.936+919G>A (also called IVS4+919G>A). In contrast, screening 81,689 females detected two heterozygotes. The novel mutations were expressed in vitro, predicting their classical or later-onset phenotypes. Newborn screening identified a surprisingly high frequency of Taiwanese males with Fabry disease (approximately 1 in 1,250), 86% having the IVS4+919G>A mutation previously found in later-onset cardiac phenotype patients. Further studies of the IVS4 later-onset phenotype will determine its natural history and optimal timing for therapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Prevalence of lysosomal storage disorders
Meikle, P. J. (1999) · JAMA · doi:10.1001/jama.281.3.249 · Cited by 2,197
Human Gene Mutation Database (HGMD®): 2003 update: HGMD 2003 UPDATE
Stenson, P. D., Ball, E. V., Mort, M., Phillips, A. D., Shiel, J. A., Thomas, N. S. T., Abeysinghe, S., Krawczak, M., & Cooper, D. N. (2003) · Human Mutation · doi:10.1002/humu.10212 · Cited by 1,829
Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's Disease
Eng, C. M., Guffon, N., Wilcox, W. R., Germain, D. P., Lee, P., Waldek, S., Caplan, L., Linthorst, G. E., & Desnick, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107053450102 · Cited by 1,559
Self-citationHigh Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*
Spada, M., Pagliardini, S., Yasuda, M., Tukel, T., Thiagarajan, G., Sakuraba, H., Ponzone, A., & Desnick, R. J. (2006) · The American Journal of Human Genetics · doi:10.1086/504601 · Cited by 1,008
Self-citationDesnick, R. J., Brady, R., Barranger, J., Collins, A. J., Germain, D. P., Goldman, M., Grabowski, G., Packman, S., & Wilcox, W. R. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-4-200302180-00014 · Cited by 766
Self-citationAn Atypical Variant of Fabry's Disease in Men with Left Ventricular Hypertrophy
Nakao, S., Takenaka, T., Maeda, M., Kodama, C., Tanaka, A., Tahara, M., Yoshida, A., Kuriyama, M., Hayashibe, H., Sakuraba, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508033330504 · Cited by 763
Prevalence of Anderson-Fabry Disease in Male Patients With Late Onset Hypertrophic Cardiomyopathy
Sachdev, B., Takenaka, T., Teraguchi, H., Tei, C., Lee, P., McKenna, W. J., & Elliott, P. M. (2002) · Circulation · doi:10.1161/01.cir.0000012626.81324.38 · Cited by 570
Agalsidase-Beta Therapy for Advanced Fabry Disease: A Randomized Trial
Banikazemi, M., Bultas, J., Waldek, S., Wilcox, W. R., Whitley, C. B., McDonald, M., Finkel, R., Packman, S., Bichet, D. G., Warnock, D. G., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-2-200701160-00148 · Cited by 569
Self-citationSAFETY AND EFFICACY OF RECOMBINANT HUMAN a -GALACTOSIDASE A REPLACEMENT THERAPY IN FABRY'S DISEASE
Ng, M., Uffon, N. A. G., Ilcox, W. I. R. W., Ermain, P. G., Ee, P., Aldek, S. T. W., Aplan, L. O. C., Inthorst, E. L., & Esnick, R. O. J. D. (2001) · Cited by 482
Cited by
Germain, D. P. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-30 · Cited by 1,198
Fabry disease revisited: Management and treatment recommendations for adult patients
Ortiz, A., Germain, D. P., Desnick, R. J., Politei, J., Mauer, M., Burlina, A., Eng, C., Hopkin, R. J., Laney, D., Linhart, A., et al. (2018) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2018.02.014 · Cited by 650
Self-citationAmendola, L. M., Jarvik, G. P., Leo, M. C., McLaughlin, H. M., Akkari, Y., Amaral, M. D., Berg, J. S., Biswas, S., Bowling, K. M., Conlin, L. K., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.03.024 · Cited by 551
Ferreira, C. R., & Gahl, W. A. (2017) · Translational Science of Rare Diseases · doi:10.3233/trd-160005 · Cited by 263
Endo‐lysosomal and autophagic dysfunction: a driving factor in Alzheimer's disease?
Whyte, L. S., Lau, A. A., Hemsley, K. M., Hopwood, J. J., & Sargeant, T. J. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.13935 · Cited by 150
Second-Generation Pharmacological Chaperones: Beyond Inhibitors
Tran, M. L., Génisson, Y., Ballereau, S., & Dehoux, C. (2020) · Molecules · doi:10.3390/molecules25143145 · Cited by 63
Newborn screening for lysosomal storage disorders and other neuronopathic conditions
Matern, D., Oglesbee, D., & Tortorelli, S. (2013) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.1117 · Cited by 41
“One program applied a tiered approach where samples with either low GAA (deficient in Pompe disease) or low α-galactosidase A (GLA; deficient in Fabry disease) were additionally tested for a control enzyme, neutral glucosidase (NAG) or β-galactosidase (GLB), respectively [Chien et al., 2008; Hwu et al., 2009].”
BackgroundMethodResultInfluentialAdeno-associated viral gene therapy for mucopolysaccharidoses exhibiting neurodegeneration
Lau, A. A., & Hemsley, K. M. (2017) · Journal of Molecular Medicine · doi:10.1007/s00109-017-1562-0 · Cited by 9
Metadata
- Authors
- Hwu, W.-L., Chien, Y.-H., Lee, N.-C., Chiang, S.-C., Dobrovolny, R., Huang, A.-C., Yeh, H.-Y., Chao, M.-C., Lin, S.-J., Kitagawa, T., Desnick, R. J., & Hsu, L.-W.
- Venue
- Human Mutation
- Publisher
- Hindawi Limited
- Published
- 2009-10
- Volume
- 30
- Issue
- 10
- Pages
- 1397-1405
- ISSN
- 1059-7794 (ISSN-L)
- 1098-1004
- OpenAlex
- W2063752042
- Cited by
- 361
- References
- 28
- FWCI
- 13.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.